Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172836 | 0.96 | PTGS1 (0.44) | PARP10PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL11587463 | 0.94 | MEN1 (0.47) | PARP10PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL17130520 | 0.92 | ACACB (0.40) | PTGS1PTGS2MEN1KMT2AMAOB | |
| SCHEMBL16483395 | 0.83 | NPC1 (0.47) | PARP10PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL3113379 | 0.83 | HAO1 (0.36) | MEN1KMT2AHRH3MAOBTDP1 | |
| SCHEMBL24179678 | 0.83 | PARP10 (0.41) | PARP10PTGS1PTGS2PDK2HRH3 | |
| SCHEMBL30609150 | 0.83 | PARP10 (0.41) | PARP10PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL16483457 | 0.83 | PTGS1 (0.48) | PARP10PTGS1PTGS2PDK2HRH3 | |
| SCHEMBL20240561 | 0.83 | PARP10 (0.45) | PARP10PTGS1PTGS2PDK2HRH3 | |
| SCHEMBL3130589 | 0.83 | HRH1 (0.55) | HRH3ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR180, GPR88 | PARP10 2285/4885PTGS1 359/4885PTGS2 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.